Lantox treatment of neurogenic dysfunction of the bladder


如何引用文章

全文:

详细

We studied correction of micturition disorders in 9 patients with neurogenic dysfunction of the bladder resistant to conservative treatment. Four patients had neurogenic detrusor hyperactivity and 5 patients had detrusor-sphincter dyssynergia. Injections of botulinic toxin preparation (lantox) were made in the wall of the bladder under endoscopic control in detrusor neurogenic hyperactivity. Women with detrusor-sphincter dyssynergia received transperineal injections of lantox in the region of external urethral sphincter. Men received botulinic toxin directly into the region of external urethral sphincter in urethroscopy. Positive results were achieved in all the cases confirming high efficacy of the method.

参考

  1. Шварц П. Г. Побочные эффекты антихолинергических средств, применяемых при лечении нейрогенных нарушений мочеиспускания. Фарматека 2005; 16: 65-71.
  2. Coffield J. A., Simpson L. L. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J., Hallet M. ed. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. 3-13.
  3. Орлова О. Р., Яхно Н. Н. Применение ботокса (токсина ботулизма типа А) в клинической практике. М.; 2001.
  4. Perkash I. Efficacy and safety of terazosin to improve voiding in spinal cord injury patients. J. Spinal Cord. Med. 1995; 18(4): 236-239.
  5. Chancellor M. B., Erhard M. J., Rivas D. A. Clinical effect of alpha-1 antagonism by terazosin on external and internal urinary sphincter function. J. Am. Paraplegia Soc. 1993; 16(4): 207-214.
  6. Abrams P., Freeman R., Anderstrom C., Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol. 1998; 81(6): 801-810.
  7. Drutz H. P., Appell R. A., Gleason D. et al. Clinical efficacy and safety of tolterodine compared to oxybutynine and placebo in patients with overactive bladder. Int. Urogynecol. J. Pelvic Floor Dysfunct. 1999; 10(5): 283-289.
  8. Appell R. A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50(6A, Suppl.): 90-96; [Discuss.: 97-99].
  9. Abrams P., Larsson G., Chapple C., Wein A. J. Factors involved in the success of antimuscarinic treatment. Br. J. Urol. Int. 1999; 83 (Suppl. 2): 42-47.
  10. Dykstra D. D., Sidi A. A., Scott A. B. et al. Effects of botulinum-A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. (Baltimore) 1988; 139(5): 919-922.
  11. Kreder K., Mayne C., Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur. Urol. 2002; 41(6): 588-595.
  12. Schurch B. Botulinum-A toxin in spinal cord injury. Arch. Phys. Med. Rehabil. 1998; 79(11): 1481.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2010
##common.cookie##